Effect of excess weight and immune-related adverse events on the efficacy of cancer immunotherapy with anti-PD-1 antibodies

Autor:	Jacobo Rogado, Nuria Romero-Laorden, José Miguel Sanchez-Torres, Ana María Ramos-Levi, Vilma Pacheco-Barcia, Ana Isabel Ballesteros, Reyes Arranz, Alicia Lorenzo, Pedro Gullon, Ana Garrido, José María Serra López-Matencio, Olga Donnay, Magdalena Adrados, Pablo Costas, Javier Aspa, Arantzazu Alfranca, Rebeca Mondejar, Ramon Colomer
Jazyk:	angličtina
Rok vydání:	2020
Předmět:	excess weight overweight obesity immune-related adverse events anti-pd-1 nivolumab pembrolizumab predictive factor advanced cancer Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Zdroj:	OncoImmunology, Vol 9, Iss 1 (2020)
Druh dokumentu:	article
ISSN:	2162-402X 2162402X
DOI:	10.1080/2162402X.2020.1751548
Popis:	Immunotherapy is an effective treatment in advanced cancer, although predictors of response are limited. We studied whether excess weight influences the efficacy outcomes of immunotherapy. We have also evaluated the combined prognostic effect of excess weight and immune-related adverse events (irAEs). Efficacy of anti-PD-1 treatment was evaluated with both objective radiological response (ORR) rate and progression-free survival (PFS), and toxicity with irAEs. We studied the association between excess weight and ORR, PFS or irAEs. 132 patients diagnosed with advanced cancer were included. Median body mass index (BMI) was 24.9 kg/m2. 64 patients had normal weight (BMI
Databáze:	Directory of Open Access Journals
Externí odkaz:	https://doaj.org/article/c17e72bb7ac94c3c8391d210e75236de Zobrazit plný text záznamu View record in DOAJ